



Revision date: 05-Mar-2018 Version: 2.0 Page 1 of 7

# 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

**Product Identifier** 

Material Name: GENTAMICIN SULFATE- gentamicin sulfate injection, solution, concentrate (Hospira, Inc.)

**Trade Name:** Gentamicin Injection **Chemical Family:** Aminoglycoside

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as antibiotic agent

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group

235 East 42nd Street New York, New York 10017

1-800-879-3477

**Emergency telephone number (North America):** 

CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Hospira Australia Pty Ltd

11 Lexia Place Mulgrave VIC 3170

**Australia** 

**Emergency telephone number (Australia):** 

International CHEMTREC (24 hours): +1-703-527-3887

## 2. HAZARDS IDENTIFICATION

## Classification of the Substance or Mixture GHS - Classification

Skin Sensitization: Category 1 Reproductive Toxicity: Category 1A

#### **Label Elements**

Signal Word: Danger

Hazard Statements: H317 - May cause an allergic skin reaction H360 - May damage fertility or the unborn child

Precautionary Statements: P201 - Obtain special instructions before use

P202 - Do not handle until all safety precautions have been read and understood

P261 - Avoid breathing dust/fume/gas/mist/vapors/spray

P272 - Contaminated work clothing must not be allowed out of the workplace

P281 - Use personal protective equipment as required

P302+ P352 - IF ON SKIN: Wash with plenty of soap and water
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention

P363 - Wash contaminated clothing before reuse

P405 - Store locked up

P501 - Dispose of contents/container in accordance with all local and national regulations

\_\_\_\_\_

Material Name: GENTAMICIN SULFATE- gentamicin sulfate

injection, solution, concentrate (Hospira, Inc.)

Revision date: 05-Mar-2018 Version: 2.0



Other Hazards An Occupational Exposure Value has been established for one or more of the ingredients (see

Section 8).

**Note:** This document has been prepared in accordance with standards for workplace safety, which

requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases.

Page 2 of 7

Your needs may vary depending upon the potential for exposure in your workplace.

# 3. COMPOSITION / INFORMATION ON INGREDIENTS

### **Hazardous**

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Gentamicin sulfate	1405-41-0	215-778-9	Repr. Cat.1A (H360) Skin Sens. 1 (H317)	1-10

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Water for injection	7732-18-5	231-791-2	Not Listed	*

Additional Information: \* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

## 4. FIRST AID MEASURES

**Description of First Aid Measures** 

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of For information on potential signs and symptoms of exposure, See Section 2 - Hazards

**Exposure:** Identification and/or Section 11 - Toxicological Information.

Page 3 of 7

Material Name: GENTAMICIN SULFATE- gentamicin sulfate

injection, solution, concentrate (Hospira, Inc.)

Revision date: 05-Mar-2018 Version: 2.0

Medical Conditions None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

# 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides and other

**Products:** sulfur-containing compounds.

Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

## 6. ACCIDENTAL RELEASE MEASURES

### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

## **Environmental Precautions**

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

## Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Contain the source of the spill if it is safe to do so. Absorb spills with non-combustible

**Collecting:** absorbent material and transfer into a labeled container for disposal.

Additional Consideration for Non-essential personnel should be evacuated from affected area. Report emergency

Large Spills: situations immediately. Cleanup operations should only be undertaken by trained personnel.

# 7. HANDLING AND STORAGE

### **Precautions for Safe Handling**

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

## Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

## **Control Parameters**

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Material Name: GENTAMICIN SULFATE- gentamicin sulfate

injection, solution, concentrate (Hospira, Inc.)

Revision date: 05-Mar-2018 Version: 2.0

# 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Gentamicin sulfate

Pfizer Occupational Exposure OEB 2 (control exposure to the range of 100ug/m³ to < 1000ug/m³)

Band (OEB):

**Exposure Controls** 

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

Refer to applicable national standards and regulations in the selection and use of personal

Page 4 of 7

contamination levels below the exposure limits listed above in this section.

**Personal Protective** 

**Equipment:** protective equipment (PPE). Contact your safety and health professional or safety equipment

supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and

specific operational processes.

Hands: Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is

possible and for bulk processing operations. (Protective gloves must meet the standards in

accordance with EN374, ASTM F1001 or international equivalent.)

Eyes: Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the

standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

**Skin:** Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations. (Protective clothing must meet the standards in accordance

with EN13982, ANSI 103 or international equivalent.)

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is

exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international

equivalent.)

# 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Sterile solution Color: Colorless

Odor: No data available. Odor Threshold: No data available.

Molecular Formula: Mixture Molecular Weight: Mixture

Solvent Solubility: No data available Water Solubility: No data available

pH: No data available.

Melting/Freezing Point (°C): No data available

Boiling Point (°C): No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Water for injection No data available Gentamicin sulfate No data available

**Decomposition Temperature (°C):** No data available.

Evaporation Rate (Gram/s):

Vapor Pressure (kPa):

Vapor Density (g/ml):

Relative Density:

No data available

Flammablity:

Material Name: GENTAMICIN SULFATE- gentamicin sulfate

injection, solution, concentrate (Hospira, Inc.)

Revision date: 05-Mar-2018 Version: 2.0

No data available Autoignition Temperature (Solid) (°C): Flammability (Solids): No data available Flash Point (Liquid) (°C): No data available **Upper Explosive Limits (Liquid) (% by Vol.):** No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available Will not occur Polymerization:

## 10. STABILITY AND REACTIVITY

Reactivity: No data available

Stable under normal conditions of use. **Chemical Stability:** 

**Possibility of Hazardous Reactions** 

**Oxidizing Properties:** No data available

Fine particles (such as dust and mists) may fuel fires/explosions. **Conditions to Avoid: Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

No data available **Hazardous Decomposition** 

**Products:** 

## 11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

**General Information:** The information included in this section describes the potential hazards of the individual

ingredients.

Repeat-dose studies in animals have shown a potential to cause adverse effects on kidneys Long Term: **Known Clinical Effects:** May cause effects similar to those seen in clinical use including transient diarrhea, nausea and

abdominal pain. Adverse effects most commonly reported in clinical use include effects on hearing, nausea, vomiting, and vertigo (vestibular ototoxicity), nervous system/brain toxicity (neurotoxicity), kidney toxicity (nephrotoxicity). May cause adverse effects on the developing

Page 5 of 7

fetus. Serious allergic reactions, including anaphylaxis, have been reported.

# Acute Toxicity: (Species, Route, End Point, Dose)

Gentamicin sulfate

Rat Oral LD50 > 5000 mg/kg LD50 96mg/kg Rat Para-periosteal Intramuscular LD50 384mg/kg Rat

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable **Acute Toxicity Comments:** 

at the highest dose used in the test.

### Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Gentamicin sulfate

Embryo / Fetal Development Intraperitoneal375 mg/kg/day LOAEL Developmental toxicity Prenatal & Postnatal Development Rat Subcutaneous 660 mg/kg/day LOAEL Developmental toxicity Prenatal & Postnatal Development Rat Subcutaneous 660 mg/kg/day LOAEL Neonatal toxicity,

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Gentamicin sulfate

**DNA Binding Assay** E. coli Negative

PZ03621

Page 6 of 7

Material Name: GENTAMICIN SULFATE- gentamicin sulfate

injection, solution, concentrate (Hospira, Inc.)

Revision date: 05-Mar-2018 Version: 2.0

# 11. TOXICOLOGICAL INFORMATION

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

# 12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment

should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

## 13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

## 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, ADG or IMDG regulations.

# 15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Gentamicin sulfate

CERCLA/SARA 313 Emission reporting Not Listed

\_\_\_\_\_

Page 7 of 7

Material Name: GENTAMICIN SULFATE- gentamicin sulfate

injection, solution, concentrate (Hospira, Inc.)

Revision date: 05-Mar-2018 Version: 2.0

# 15. REGULATORY INFORMATION

California Proposition 65 Aminoglycosides- developmental

Australia (AICS): Present EU EINECS/ELINCS List 215-778-9

Water for injection

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

REACH - Annex IV - Exemptions from the

Present

Present

obligations of Register:

EU EINECS/ELINCS List 231-791-2

# 16. OTHER INFORMATION

### Text of CLP/GHS Classification abbreviations mentioned in Section 3

Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction Reproductive toxicity-Cat.1A; H360 - May damage fertility or the unborn child

Data Sources: Publicly available toxicity information. Safety data sheets for individual ingredients. Pfizer

proprietary drug development information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 16 - Other Information.

Revision date: 05-Mar-2018

Product Stewardship Hazard Communications

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.

**End of Safety Data Sheet** 

\_\_\_\_\_